What is the Optimal antiplatElet & anticoagulant therapy in patients with oral anticoagulation and coronary StenTing

Phase 4

• Conditions: Atrial fibrillation = Heart rhythm disorder; percutaneous coronary intervention= stenting; 10082206

• Registration Number: NL-OMON35700
• Lead Sponsor: Sint Antonius Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 496

Inclusion Criteria

Patient under warfarin treatment such as patients with atrial fibrillation, mechanical valve... AND with indication for percutaneous coronary intervention

Exclusion Criteria

cardiogenic shock, contra-indication for aspirin or clopidogrel, documented peptic ulcer disease within the previous six months, pregnancy and previous intracerebral haemorrhage or significant thrombocytopenia (platelet count < 50x10 9/L).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The combined end point of minor, moderate or major bleeding complications<br /><br>during the initial hospitalization & one year follow-up.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The combined event of death, myocardial infarction, stroke, systemic<br /><br>embolisation & target vessel revascularisation and the individual components of<br /><br>the composite primary and secondary endpoints. </p><br>